## Marginal miss, recovery in sight

ITC's 4Q was marginally lower than estimates but lockdown impact was not as severe as it was visible in other cos. Net revenue was down by $6 \%$ yoy while HUL/Dabur/Colgate/Marico clocked decline of 9/17/7/8\% yoy in the domestic business. Cig revenues declined by $\mathbf{6 \%}$ yoy with $\sim 10 \%$ yoy volume dip. FMCG comparable growth of $5 \%$ yoy was better than estimate (even better than Britannia's 2\% growth). Recovery in Cig and FMCG in May and June is encouraging. FMCG, Paperboards and Packaging are now operating at $80-85 \%$ of normal levels. Co has not witnessed downtrading trend or any meaningful drop-outs of cig consumers due to lockdown. Packaged food enjoyed pantry loading benefits and part of personal care also recovered. Co has good portfolio to capitalise on health and hygiene trend. FCF grew by robust $30 \%$ yoy, FCF and dividend yield stands at $7 \%$ and $5 \%$ in FY20. We cut EPS estimate by $5 \%$ for FY21 to factor impact of extended lockdown. We value ITC on SoTP and arrive at a TP of Rs 221 (implied P/E of 17x). Risk reward remains attractive. Maintain BUY.

- Marginal miss in revenue: Revenues dipped by $6 \%$ yoy for ITC ( $+13 \%$ in 4QFY19 and $+5 \%$ in 3QFY20) vs HSIE est of $2 \%$ yoy decline. Cigarette/Hotels/Agri/Paper saw revenue decline of $7 / 9 / 10 / 5 \%$ yoy while FMCG biz saw LFL revenue growth of 5\% yoy. Cigarettes saw the impact from the dual shock of excise hike and Covid-19 while the Hotels biz was severely impacted by consumers cutting back on travel. Paper biz was also severely impacted as co lost out on sales during March, which is typically the prime period for offtake in the segment.
- Cig margin falls, FMCG margin continues to expand: GM expanded by 220bps yoy (-81bps in 4QFY19 and -23bps in 3QFY20) to $64.4 \%$ Cig EBIT declined by $12 \%$ yoy as the sharp increase in prices led to downtrading among consumers. FMCG saw EBITDA growth of $12 \%$ yoy ( $32 \%$ in FY20) while Hotels/Agri/Paper saw EBIT decline of 52/16/9\% yoy. EBITDA declined by $9 \%$ yoy ( $+10 \%$ in 4QFY19 and $+7 \%$ in 3QFY20) to Rs 41.64bn (HSIE Rs 44.22 bn ). PAT grew by $9 \%$ yoy to Rs 37.97 bn (HSIE Rs 33.73bn) owing to lower taxes.
- Press release \& other takeaways: (1) FMCG biz was headed for double digit growth in Jan/Feb, (2) Co is functioning at close to $100 \%$ over the last few days, (3) Co has made significant new launches in FMCG and Hygiene, (4) FCF grew by $30 \%$ in FY20 vs. FY19, (5) Co has implemented several initiatives to use automation and process optimization to control costs and (6) Co continued to make strategic acquisitions (Sunrise Foods, B-Naturals, Savlon, Nimyle, etc) in order to expand its footprint.
Financial Summary

| YE Mar (Rs mn) | 4QFY20 | 4QFY19 | YoY <br> (\%) | 3QFY20 | QoQ <br> (\%) | FY19 | FY20P | FY21E | FY22E |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net Sales | 114,200 | 122,060 | $(6.4)$ | 120,130 | $(4.9)$ | 483,527 | 494,041 | 476,483 | 539,692 |
| EBITDA | 41,635 | 45,717 | $(8.9)$ | 46,127 | $(9.7)$ | 184,064 | 192,602 | 180,836 | 206,800 |
| APAT | 37,971 | 34,324 | 10.6 | 37,766 | 0.5 | 127,864 | 152,275 | 139,404 | 159,332 |
| Diluted EPS (Rs) | 3.1 | 2.8 | 10.3 | 3.1 | 0.5 | 10.4 | 12.4 | 11.3 | 13.0 |
| P/E (x) |  |  |  |  |  | 18.7 | 15.7 | 17.2 | 15.0 |
| EV / EBITDA (x) |  |  |  |  |  | 11.5 | 10.7 | 11.3 | 9.7 |
| RoCE (\%) |  |  |  |  | 39.2 | 44.8 | 39.3 | 44.2 |  |

BUY


Source : BSE

Varun Lohchab
varun.lohchab@hdfcsec.com
+91-22-6171-7334

Naveen Trivedi
naveen.trivedi@hdfcsec.com
+91-22-6171-7324

## Aditya Sane

aditya.sane@hdfcsec.com
+91-22-6171-7336

INSTITUTIONAL RESEARCH
Quarterly Financial Snapshot

| Particulars | 4QFY20 | 4QFY19 | YoY (\%) | 3QFY20 | $\begin{gathered} \text { QoQ } \\ \text { (\%) } \end{gathered}$ | FY20P | FY19 | YoY (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net Revenue | 113,001 | 120,642 | (6.3) | 119,122 | (5.1) | 463,237 | 452,214 | 2.4 |
| Other operating revenue | 1,200 | 1,419 | (15.4) | 1,009 | 19.0 | 4,836 | 5,630 | (14.1) |
| Total Revenue | 114,200 | 122,060 | (6.4) | 120,130 | (4.9) | 468,073 | 457,844 | 2.2 |
| Material Expenses | 40,671 | 46,156 | (11.9) | 45,465 | (10.5) | 172,351 | 173,052 | (0.4) |
| Employee Expenses | 6,665 | 7,600 | (12.3) | 6,691 | (0.4) | 26,582 | 27,284 | (2.6) |
| Other Operating Expenses | 25,229 | 22,588 | 11.7 | 21,847 | 15.5 | 90,098 | 84,453 | 6.7 |
| EBITDA | 41,635 | 45,717 | (8.9) | 46,127 | (9.7) | 179,043 | 173,055 | 3.5 |
| Depreciation | 3,925 | 3,502 | 12.1 | 4,162 | (5.7) | 16,449 | 13,966 | 17.8 |
| EBIT | 37,710 | 42,215 | (10.7) | 41,965 | (10.1) | 162,593 | 159,089 | 2.2 |
| Other Income | 7,555 | 7,402 | 2.1 | 9,836 | (23.2) | 30,137 | 24,845 | 21.3 |
| Interest Cost | 147 | 77 | 90.3 | 124 | 18.4 | 557 | 342 | 63.0 |
| PBT before exceptional | 45,118 | 49,539 | (8.9) | 51,676 | (12.7) | 192,989 | 184,442 | 4.6 |
| Exceptional | - | - | na | $(1,321)$ | na | $(1,321)$ | - | na |
| PBT | 45,118 | 49,539 | (8.9) | 50,355 | (10.4) | 191,668 | 184,442 | 3.9 |
| Tax | 7,148 | 14,720 | (51.4) | 8,936 | (20.0) | 40,308 | 59,798 | (32.6) |
| RPAT | 37,971 | 34,819 | 9.1 | 41,419 | (8.3) | 151,361 | 124,643 | 21.4 |
| Adjustment | - | (495) | na | $(3,653)$ | na | $(3,653)$ | (495) | na |
| APAT | 37,971 | 34,324 | 10.6 | 37,766 | 0.5 | 147,708 | 124,148 | 19.0 |
| EPS | 3.1 | 2.8 | 10.3 | 3.1 | 0.5 | 12.0 | 10.1 | 19.0 |

Source: Company, HSIE Research
Quarterly Performance Analysis

| MARGIN ANALYSIS <br> (\% of Net Sales) | 4QFY20 | 4QFY19 | YoY <br> (bps) | 3QFY20 | QoQ <br> $\mathbf{( b p s )}$ | FY20P | FY19 | YoY <br> (bps) |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Material Expenses | 35.6 | 37.8 | $(220)$ | 37.8 | $(223)$ | 36.8 | 37.8 | $(98)$ |
| Employee Expenses | 5.8 | 6.2 | $(39)$ | 5.6 | 27 | 5.7 | 6.0 | $(28)$ |
| Other Expenses | 22.1 | 18.5 | 359 | 18.2 | 391 | 19.2 | 18.4 | 80 |
| EBITDA Margin | 36.5 | 37.5 | $(100)$ | 38.4 | $\mathbf{( 1 9 4 )}$ | 38.3 | 37.8 | $\mathbf{4 5}$ |
| Tax Rate | 15.8 | 29.7 | $(1,387)$ | 17.7 | $(190)$ | 21.0 | 32.4 | $(1,139)$ |
| APAT Margin | 33.2 | 28.1 | 513 | 31.4 | 181 | 31.6 | 27.1 | 444 |

Source: Company, HSIE Research

## Quarterly Segmental Performance

| (Rs mn) | 4QFY20 | 4QFY19 | YoY <br> (\%) | 3QFY20 | QoQ <br> (\%) | FY20P | FY19 | YoY <br> (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Segmental Revenues |  |  |  |  |  |  |  |  |
| Cigarettes | 51,305 | 54,859 | 6.0 | 53,110 | (3.4) | 2,12,017 | 2,07,130 | 10.0 |
| FMCG | 31,836 | 32,739 | 6.5 | 33,123 | (3.9) | 1,28,442 | 1,25,053 | 12.6 |
| Hotels | 4,658 | 5,098 | 17.7 | 5,523 | (15.7) | 18,373 | 16,655 | 10.3 |
| Agribusiness | 18,873 | 21,009 | 19.3 | 20,947 | (9.9) | 1,02,407 | 93,965 | 9.0 |
| Paperboards, Paper \& Packaging | 14,589 | 15,374 | 9.9 | 15,554 | (6.2) | 61,072 | 58,602 | 4.2 |
| Total | 1,21,260 | 1,29,079 | 8.7 | 1,28,257 | (5.5) | 5,22,311 | 5,01,404 | 4.2 |
| Less: Inter-segment revenue | 8,259 | 8,437 | (2.1) | 9,135 | (9.6) | 59,074 | 49,190 | 20.1 |
| Total | 1,13,001 | 1,20,642 | (6.3) | 1,19,122 | (5.1) | 4,63,237 | 4,52,214 | 2.4 |
| Segmental EBIT |  |  |  |  |  |  |  |  |
| Cigarettes | 34,030 | 38,560 | (11.7) | 37,560 | (9.4) | 1,48,526 | 1,45,511 | 2.1 |
| FMCG | 1,470 | 2,010 | (26.9) | 1,076 | 36.5 | 4,231 | 3,862 | 9.5 |
| Hotels | 426 | 887 | (52.0) | 873 | (51.2) | 1,578 | 1,777 | (11.2) |
| Agribusiness | 1,231 | 1,472 | (16.4) | 2,134 | (42.3) | 7,889 | 7,766 | 1.6 |
| Paperboards, Paper \& Packaging | 2,857 | 3,005 | (4.9) | 3,340 | (14.5) | 13,053 | 12,392 | 5.3 |
| Total | 40,014 | 45,934 | (12.9) | 44,983 | (11.0) | 1,75,276 | 1,71,309 | 2.3 |
| Less: |  |  |  |  |  |  |  |  |
| (a) Interest Cost \& Bank Charges | 147 | 77 | 90.3 | 124 | 18.4 | 557 | 342 | 63.0 |
| (b) Other Un-allocable Expenses | $(5,252)$ | $(3,683)$ | 42.6 | $(6,818)$ | (23.0) | $(18,270)$ | $(13,475)$ | 35.6 |
| PBT | 45,118 | 49,539 | (8.9) | 51,676 | (12.7) | 1,92,989 | 1,84,442 | 4.6 |
| Capital Employed |  |  |  |  |  |  |  |  |
| Cigarettes | 29,128 | 35,944 | (19.0) | 34,935 | (16.6) | 29,128 | 35,944 | (19.0) |
| FMCG | 65,609 | 60,758 | 8.0 | 68,285 | (3.9) | 65,609 | 60,758 | 8.0 |
| Hotels | 57,880 | 54,079 | 7.0 | 56,915 | 1.7 | 57,880 | 54,079 | 7.0 |
| Agribusiness | 29,323 | 29,937 | (2.1) | 30,496 | (3.8) | 29,323 | 29,937 | (2.1) |
| Paperboards, Paper \& Packaging | 60,591 | 62,108 | (2.4) | 61,368 | (1.3) | 60,591 | 62,108 | (2.4) |
| Total | 2,42,532 | 2,42,826 | (0.1) | 2,51,998 | (3.8) | 2,42,532 | 2,42,826 | (0.1) |
| Unallocated corporate assets | 3,97,760 | 3,36,672 | 18.1 | 3,57,467 | 11.3 | 3,97,760 | 3,36,672 | 18.1 |
| Total capital employed | 6,40,292 | 5,79,498 | 10.5 | 6,09,465 | 5.1 | 6,40,292 | 5,79,498 | 10.5 |

Source: Company, HSIE Research

Segmental EBIT Margin

| (Rs mn) | 4QFY20 | 4QFY19 | YoY <br> (bps) | 3QFY20 | QoQ <br> $(b p s)$ | FY20P | FY19 | Yo <br> $(b p s)$ |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cigarettes | 66.3 | 70.3 | $(396)$ | 70.7 | $(439)$ | 70.1 | 75.5 | $(544)$ |
| FMCG | 4.6 | 6.1 | $(152)$ | 3.2 | 137 | 3.3 | 3.1 | 21 |
| Hotels | 9.1 | 17.4 | $(825)$ | 15.8 | $(667)$ | 8.6 | 10.7 | $(209)$ |
| Agribusiness | 6.5 | 7.0 | $(49)$ | 10.2 | $(367)$ | 7.7 | 8.3 | $(56)$ |
|  <br> Packaging | 19.6 | 19.5 | 4 | 21.5 | $(189)$ | 21.4 | 21.1 | 23 |
| Total | 33.0 | $\mathbf{3 5 . 6}$ | $\mathbf{( 2 5 9 )}$ | $\mathbf{3 5 . 1}$ | $\mathbf{( 2 0 7 )}$ | $\mathbf{3 3 . 6}$ | $\mathbf{3 4 . 2}$ | $\mathbf{( 6 1 )}$ |

Source: Company, HSIE Research

Cigarette Value Growth


Source: Company, HSIE Research

Cigarette Price Growth


Source: Company, HSIE Research

FMCG Revenue Growth


[^0]Cigarette Volume Growth


Source: Company, HSIE Research

Cigarette EBIT Growth


Source: Company, HSIE Research

Hotel Revenue Growth


[^1]

Source: Company, HSIE Research

FMCG Revenue Mix: Packaged Food Dominates


Source: Company, HSIE Research

FMCG Revenue Product Mix


[^2]

Source: Company, HSIE Research

Top FMCG Brands (Size at consumer level)


Source: Company, HSIE Research

FMCG EBIT margins: ~10\% swing over FY11-20


[^3]FMCG segment mapping: ITC's addressable market offers a 13x opportunity headroom

| Brand | Current Presence | Possible Extension | Brand Position | Mkt Position | Est. Market <br> Size (Rs mn) | Est. ITC Revenue at Consumer level (Rs mn) | Key competitors |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Food |  |  |  |  |  |  |  |
| Aashirvaad | - Wheat <br> - Ghee <br> - Spices <br> - Instant mixes <br> - Read-to-eat <br> - Rice <br> - Milk, Curd, Paneer <br> - Salt | - Pickles <br> - Grains (white flour, semolina, gram flour) <br> - Distribution expansion of new launches | Mid | No. 1 | 150,000 | 45,000 | - Pillsbury Atta (General Mills) - Silver Coin (Sanghvi Group) <br> - Mother's Recipe |
| Sunfeast | - Biscuits <br> - Cookies <br> - Cake <br> - Beverage <br> - Pasta | - Modern milk <br> products <br> - Rusk/Bread <br> - Chocolates <br> - Oats <br> - Breakfast packaged food | Mid to <br> Premium | No. 1 in premium biscuit segment | 590,000 | 38,000 | - Britannia, Parle, <br> PriyaGold, Anmol |
| Bingo | - Extruded snacks <br> - Potato Chips | - Healthy variants in salty snacks | Mid to <br> Premium | No. 1 | 219,000 | 25,000 | - Lays (Pepsi), <br> Diamond (Prataap <br> snacks), Too <br> Yumm!, Haldiram |
| YiPPee | - Noodles <br> - Pasta | - Oats | Mid | No. 2 | 153,000 | 11,000 | - Maggi (Nestle), Top Ramen (Nissin) |
| Mint-o, <br> Candyman, GumOn | - Confectionery | - More variants | Mid | Top 5 | 40,800 | 6,000 |  |
| B-Naturals | - Juices | - More variants <br> - Healthy supplements | Mid to <br> Premium | Emerging | 20,000 | 4,800 | - Real (Dabur), <br> Tropicana (Pepsi) |
| Fabelle | - Chocolate | - Mass premium <br> - Eventually, capture full portfolio | Superpremium | Emerging | 80,000 | 150 | - Cadburry <br> (Mondelez), Nestle |
| Sunbean | - Coffee paste | - Ready to drink <br> - Distribution expansion | Premium | Emerging | 15,000 | 100 | - Nescafe (Nestle), <br> Bru (HUL) |
| ITC Master Chef | - Ready-to-eat <br> - Frozen foods (prawns) <br> - Fresh vegetables and fruits <br> - Spices <br> - Masala | - Variants in frozen foods <br> - Distribution expansion | Mid to <br> Premium | Emerging | 4,000 |  |  |
| Personal Care |  |  |  |  |  |  |  |
| Fiama | - Shower Gel <br> - Soap Bar <br> - Talc | - Shampoo <br> - Shaving Cream <br> - Talc <br> - Face wash | Premium | No. 2 | 20,000 | 3,600 | - Nivea: leader with $20 \%$ share (Beiersdorf Global) <br> - Palmolive <br> - Dove |
| Vivel Superia | - Soap Bar <br> - Soap Bar | -More variants <br> -More variants | Mid <br> Mass | $\begin{aligned} & \text { na } \\ & \text { na } \end{aligned}$ | 200,000 | 6,000 | - Lux, Lifebuoy, Dove, Pears, Hamam (HUL) - Godrej No 1, Cinthol (GCPL) - Santoor (Wipro) <br> - Dettol (RB) |


| Brand | Current Presence | Possible Extension | Brand <br> Position | Mkt Position | Est. Market <br> Size (Rs mn) | Est. ITC Revenue at Consumer level (Rs mn) | Key competitors |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Superia | - Shampoo | -More variants | Mass | na | 60,000 |  |  |
| Engage | - Deos <br> - Perfume <br> - Pocket Perfume | - Face Wash <br> - Talc <br> - More variants | Mid to <br> Premium | No. 2 | 30,000 | 3,300 | - Fogg : market leader with $17 \%$ <br> (Vini) <br> - Wild Stone <br> - Nivea <br> - Park Avenue <br> - Axe |
| Essenza Di Wills | - Perfume | - Face cream <br> - Moisturiser <br> - Deo | Superpremium | Emerging | 20,000 | na | - Fogg (Vini) <br> - Skinn (Titan) <br> - Park Avenue <br> (Raymond) |
| Savlon | - Anti-septic liquid <br> - Soaps <br> - Handwash <br> - Hand sanitizer | - Hand wash <br> - Shaving Cream <br> - Shower Gel <br> - Disinfectant liquid | Mid | No. 2 | 10,000 | 2,000 | - Dettol (RB) |
| Charmis | - Cold cream | - Moisturiser | Mid | na | na | na | - Nivea (Beiersdorf Global) <br> - Pond's (HUL) |
| Dermafique | - Anti-aging | - More variants | Premium | Emerging | na | na | - Olay (P\&G) <br> - Lakme (HUL) <br> - Nivea (BG) |
| Shower to <br> Shower | - Talc | - Shower Gel <br> - Soap Bar <br> - Talc | Mid | na | 4,000 | 240 | - Himalaya <br> - Dermi Cool (RB) <br> - Boroplus <br> (Emami) <br> - Nycil (Kraft <br> Heinz) |
| Home Care |  |  |  |  |  |  |  |
| Nimyle | Floor Cleaner | - Kitchen cleaner <br> - More Variants | Mid | Emerging | 100,000 | na | - Lizol (RB) <br> - Domex (HUL) <br> - Mr. Muscle (SC <br> Johnson) |
| Others |  |  |  |  |  |  |  |
| Classmate <br> Paperkraft | - Notebooks <br> - Pen <br> - Pencil <br> - Geometric box <br> - Art instruments | - More variants <br> - Office stationery | Premium | No. 2 | 100,000 | 10,000 | - Navneet <br> - Luxor <br> - BILT (Balrampur) |
| Wills | Life Style | - Restructure business | Premium | na | na | 7,185 | - All leading mens formal wear brands |
| Aim <br> Ship | Safety Matches | - Cigarette and gas stove lighters | Mid | No. 1 | 10,000 | 2,422 | - Largely unorganised |

Home Lites

## Assumptions

| Particulars | FY15 | FY16 | FY17 | FY18 | FY19 | FY20P | FY21E | FY22E |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cigarette |  |  |  |  |  |  |  |  |
| Revenue Gr (\%) | 4.7 | 6.2 | 5.1 | 4.9 | 10.0 | 2.5 | (8.8) | 12.7 |
| Volume Gr (\%) | (8.8) | (8.8) | 1.4 | (3.0) | 5.6 | (0.4) | (4.9) | 5.9 |
| Cig. Price Gr (\%) | 13.5 | 15.0 | 3.7 | 7.9 | 4.4 | 2.9 | (4.0) | 6.8 |
| EBIT Gr (\%) | 11.8 | 5.0 | 6.5 | 6.6 | 9.1 | 2.1 | (8.2) | 13.8 |
| FMCG |  |  |  |  |  |  |  |  |
| Revenue Gr (\%) | 11.3 | 7.7 | 8.0 | 11.3 | 12.6 | 2.9 | 14.7 | 10.8 |
| EBIT Margin (\%) | 0.4 | 0.7 | 0.3 | 1.4 | 2.5 | 3.3 | 4.1 | 4.6 |
| Hotel |  |  |  |  |  |  |  |  |
| Revenue Gr (\%) | 4.6 | 11.5 | 1.6 | 5.6 | 17.3 | 10.3 | (31.1) | 20.0 |
| EBIT Gr (\%) | (64.9) | 13.4 | 99.3 | 26.0 | 27.1 | (11.2) | (21.3) | 27.2 |
| EBIT Margin (\%) | 4.1 | 4.3 | 8.3 | 9.9 | 10.7 | 8.6 | 9.8 | 10.4 |
| Agri business |  |  |  |  |  |  |  |  |
| Revenue Gr (\%) | 10.6 | 0.2 | (5.8) | (15.0) | 16.9 | 10.7 | 10.4 | 10.4 |
| EBIT Gr (\%) | 8.3 | 2.8 | (2.6) | (6.3) | (8.5) | 1.6 | (5.0) | 18.2 |
| EBIT Margin (\%) | 10.8 | 12.5 | 11.0 | 10.5 | 8.3 | 7.7 | 8.1 | 8.1 |
| Paper \& Paper boards |  |  |  |  |  |  |  |  |
| Revenue Gr (\%) | 11.2 | 5.9 | (0.8) | (0.7) | 10.1 | 11.5 | 11.6 | 11.7 |
| EBIT Gr (\%) | 3.3 | (1.5) | 6.4 | 7.9 | 18.9 | 5.3 | (8.7) | 16.9 |
| EBIT Margin (\%) | 18.5 | 17.0 | 18.0 | 19.9 | 21.1 | 21.4 | 21.0 | 21.3 |
| Gross Margin (\%) | 61.6 | 65.4 | 62.5 | 63.5 | 64.0 | 64.9 | 64.2 | 64.3 |
| Employee (\% of sales) | 7.2 | 8.8 | 8.5 | 8.7 | 8.6 | 8.7 | 9.0 | 8.5 |
| ASP (\% of sales) | 2.2 | 2.5 | 1.9 | 2.1 | 2.1 | 2.1 | 1.8 | 2.0 |
| Distribution (\% of sales) | 2.4 | 2.2 | 2.0 | 2.1 | 2.4 | 2.3 | 2.2 | 2.3 |
| Other Expenses (\% of sales) | 13.8 | 15.0 | 14.1 | 12.8 | 12.8 | 12.8 | 13.3 | 13.2 |
| EBITDA Margin (\%) | 36.0 | 36.9 | 36.1 | 37.9 | 38.1 | 39.0 | 38.0 | 38.3 |
| Tax Rate (\%) | 32.0 | 36.1 | 34.6 | 34.0 | 33.0 | 22.2 | 25.2 | 25.2 |

SOTP Valuation

| Particulars (Rs mn) | Criteria | Value |
| :--- | :--- | :---: |
| Cigarette | EBITDA (Rs mn) | 163 |
|  | EV/EBITDA (x) | 11 |
| FMCG | EV (Rs mn) | 1,793 |
|  | Revenue (Rs mn) | 163 |
| Hotel | EV/Revenue (x) | 2 |
|  | EV (Rs mn) | 326 |
| Agri | EBITDA (Rs mn) | 4 |
|  | EV/EBITDA (x) | 8 |
| Paper | EV (Rs mn) | 34 |
|  | EBITDA (Rs mn) | 10 |
| Total EV | EV/EBITDA (x) | 8 |
| Cash Investment | EV (Rs mn) | 78 |
| Debt | EBITDA (Rs mn) | 18 |
| Mkt Cap | EV/EBITDA (x) | 8 |
| TP | EV (Rs mn) | 145 |

Change in Estimates

|  | FY21E |  |  | FY22E |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
|  | NEW | OLD | Chg (\%) | NEW | OLD | Chg (\%) |
|  | 476,483 | 499,255 | $(4.6)$ | 539,692 | 544,484 | $(0.9)$ |
| EBITDA | 180,836 | 184,640 | $(2.1)$ | 206,800 | 202,199 | 2.3 |
| APAT | 139,404 | 146,098 | $(4.6)$ | 159,332 | 159,333 | $(0.0)$ |
| EPS | 11.3 | 11.9 | $(4.8)$ | 13.0 | 13.0 | $(0.3)$ |

Peer Set Comparison

| Company | Mcap <br> (Rs <br> bn) | $\begin{aligned} & \text { CMP } \\ & \text { (Rs/sh) } \end{aligned}$ | Reco | TP | EPS (Rs) |  |  | P/E (x) |  |  | EV/EBITDA (x) |  |  | Core RoCE (\%) |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | $\begin{aligned} & \text { FY20P/ } \\ & \text { CY19P } \end{aligned}$ | $\begin{aligned} & \text { FY21E/ } \\ & \text { CY20E } \end{aligned}$ | $\begin{gathered} \text { FY22E/ } \\ \text { CY21E } \end{gathered}$ | $\begin{aligned} & \text { FY20P/ } \\ & \text { CY19P } \end{aligned}$ | $\begin{aligned} & \text { FY21E/ } \\ & \text { CY20E } \end{aligned}$ | $\begin{gathered} \text { FY22E/ } \\ \text { CY21E } \end{gathered}$ | FY20P/ <br> CY19P | $\begin{aligned} & \text { FY21E/ } \\ & \text { CY20E } \end{aligned}$ | $\begin{gathered} \hline \text { FY22E/ } \\ \text { CY21E } \end{gathered}$ | FY20P/ CY19P | $\begin{aligned} & \text { FY21E/ } \\ & \text { CY20E } \end{aligned}$ | $\begin{aligned} & \text { FY22E/ } \\ & \text { CY21E } \end{aligned}$ |
| HUL | 4,656 | 2,151 | REDUCE | 1,969 | 31.7 | 37.1 | 41.9 | 67.9 | 58.0 | 51.5 | 46.5 | 40.0 | 35.6 | 230.7 | 46.5 | 28.8 |
| ITC | 2,399 | 195 | BUY | 221 | 12.4 | 11.3 | 13.0 | 15.7 | 17.2 | 15.0 | 10.7 | 11.3 | 9.7 | 44.8 | 39.3 | 44.2 |
| Nestle | 1,611 | 16,708 | REDUCE | 14,042 | 206.0 | 237.6 | 278.2 | 81.1 | 70.3 | 60.1 | 54.0 | 48.4 | 42.3 | 75.0 | 70.7 | 69.1 |
| Dabur | 811 | 461 | REDUCE | 404 | 8.6 | 9.0 | 10.1 | 53.4 | 51.0 | 45.6 | 44.4 | 41.8 | 37.0 | 44.6 | 40.6 | 44.5 |
| Britannia | 830 | 3,454 | REDUCE | 2,852 | 58.5 | 65.6 | 75.1 | 59.1 | 52.7 | 46.0 | 43.8 | 38.3 | 33.8 | 42.8 | 49.1 | 55.5 |
| GCPL | 700 | 686 | REDUCE | 529 | 14.4 | 15.7 | 17.6 | 47.6 | 43.6 | 38.9 | 33.5 | 33.0 | 30.1 | 19.0 | 18.9 | 21.4 |
| Marico | 445 | 345 | REDUCE | 283 | 8.0 | 8.4 | 9.4 | 43.0 | 40.9 | 36.5 | 30.2 | 28.8 | 26.5 | 41.8 | 43.2 | 46.5 |
| United Spirits | 431 | 593 | ADD | 586 | 10.9 | 11.0 | 14.0 | 54.5 | 53.8 | 42.4 | 29.4 | 29.4 | 24.6 | 16.0 | 19.6 | 23.5 |
| Colgate | 380 | 1,396 | ADD | 1,328 | 30.0 | 31.2 | 35.0 | 46.5 | 44.8 | 39.9 | 31.2 | 29.0 | 25.9 | 64.7 | 63.9 | 75.2 |
| Jubilant | 234 | 1,770 | REDUCE | 1,420 | 26.8 | 20.7 | 35.5 | 66.0 | 85.4 | 49.8 | 39.6 | 47.0 | 30.0 | 28.4 | 11.5 | 21.7 |
| Emami | 101 | 222 | REDUCE | 221 | 11.7 | 11.6 | 13.0 | 20.3 | 21.7 | 19.1 | 14.7 | 15.2 | 13.6 | 23.2 | 24.1 | 29.9 |
| Radico <br> Khaitan | 50 | 379 | BUY | 363 | 16.0 | 18.2 | 22.7 | 23.7 | 20.9 | 16.7 | 14.6 | 13.1 | 10.8 | 14.5 | 12.8 | 14.7 |

Source: Company, HSIE Research

Financials

## Consolidated Income Statement

| Year End (March) | FY15 | FY16 | FY17 | FY18 | FY19 | FY20P | FY21E | FY22E |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net Revenues | 384,333 | 391,921 | 428,036 | 434,489 | 483,527 | 494,041 | 476,483 | 539,692 |
| Growth (\%) | 9.9 | 2.0 | 9.2 | 4.5 | 11.3 | 2.2 | (3.6) | 13.3 |
| Material Expenses | 147,722 | 135,685 | 160,492 | 158,555 | 174,203 | 173,455 | 170,581 | 192,670 |
| Employee Expense | 27,723 | 34,410 | 36,317 | 37,609 | 41,779 | 42,958 | 42,827 | 45,983 |
| ASP Expense | 8,385 | 9,887 | 8,107 | 9,041 | 9,946 | 10,424 | 8,577 | 10,794 |
| Distribution Expense | 9,050 | 8,528 | 8,560 | 9,041 | 11,765 | 11,363 | 10,483 | 12,413 |
| Other Expenses | 53,225 | 58,903 | 60,201 | 55,414 | 61,770 | 63,239 | 63,180 | 71,032 |
| EBITDA | 138,229 | 144,509 | 154,359 | 164,830 | 184,064 | 192,602 | 180,836 | 206,800 |
| EBITDA Growth (\%) | 8.5 | 4.5 | 6.8 | 6.8 | 11.7 | 4.6 | (6.1) | 14.4 |
| EBITDA Margin (\%) | 36.0 | 36.9 | 36.1 | 37.9 | 38.1 | 39.0 | 38.0 | 38.3 |
| Depreciation | 10,279 | 10,774 | 11,528 | 12,363 | 13,966 | 16,449 | 17,739 | 19,119 |
| EBIT | 127,950 | 133,735 | 142,831 | 152,467 | 170,098 | 176,153 | 163,096 | 187,681 |
| Other Income | 16,580 | 15,308 | 17,615 | 18,319 | 21,738 | 25,979 | 23,219 | 25,234 |
| Interest | 910 | 536 | 243 | 899 | 454 | 547 | 148 | 136 |
| PBT | 143,621 | 148,507 | 160,204 | 174,016 | 191,381 | 200,264 | 186,167 | 212,780 |
| Total Tax | 45,964 | 53,582 | 55,491 | 59,164 | 63,139 | 44,418 | 46,858 | 53,557 |
| RPAT | 96,632 | 95,009 | 104,772 | 114,927 | 128,359 | 155,928 | 139,404 | 159,332 |
| Exceptional Gain/(loss) | - | - | - | 2,725 | 495 | 3,653 | - |  |
| Adjusted PAT | 96,632 | 95,009 | 104,772 | 112,202 | 127,864 | 152,275 | 139,404 | 159,332 |
| APAT Growth (\%) | 8.4 | (1.7) | 10.3 | 7.1 | 14.0 | 19.1 | (8.5) | 14.3 |
| Adjusted EPS (Rs) | 8.0 | 7.9 | 8.6 | 9.2 | 10.4 | 12.4 | 11.3 | 13.0 |
| EPS Growth (\%) | 7.6 | (2.1) | 9.6 | 6.6 | 13.5 | 18.8 | (8.5) | 14.3 |

Source: Company, HSIE Research
Consolidated Balance Sheet

| Particulars (Rs mn) | FY15 | FY16 | FY17 | FY18 | FY19 | FY20P | FY21E | FY22E |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| SOURCES OF FUNDS |  |  |  |  |  |  |  |  |
| Share Capital - Equity | 8,016 | 8,047 | 12,147 | 12,204 | 12,259 | 12,292 | 12,292 | 12,292 |
| Reserves | 309,339 | 418,748 | 451,982 | 512,897 | 565,114 | 632,552 | 647,190 | 694,999 |
| Total Shareholders Funds | 317,355 | 426,795 | 464,129 | 525,101 | 577,372 | 644,845 | 659,482 | 707,291 |
| Minority Interest | 2,251 | 2,609 | 2,947 | 3,345 | 3,435 | 3,775 | 3,680 | 3,571 |
| Long Term Debt | 607 | 267 | 184 | 115 | 82 | 59 | 59 | 59 |
| Short Term Debt | 1,954 | 440 | 191 | 174 | 19 | 14 | 16 | 17 |
| Total Debt | 2,561 | 706 | 375 | 289 | 100 | 73 | 75 | 76 |
| Net Deferred Taxes | 16,045 | 18,395 | 18,333 | 18,749 | 19,927 | 15,709 | 11,342 | 6,626 |
| Other non current liabilities | 1,668 | 2,756 | 2,174 | 2,596 | 2,419 | 3,194 | 3,194 | 3,194 |
| TOTAL SOURCES OF FUNDS | 339,880 | 451,261 | 487,959 | 550,080 | 603,253 | 667,596 | 677,773 | 720,759 |
| APPLICATION OF FUNDS |  |  |  |  |  |  |  |  |
| Net Block | 150,674 | 149,060 | 157,778 | 163,907 | 191,530 | 201,343 | 212,152 | 219,733 |
| CWIP | 31,116 | 35,759 | 49,180 | 77,353 | 63,618 | 54,873 | 48,369 | 43,167 |
| Goodwill | 2,369 | 2,314 | 2,314 | 2,314 | 2,314 | 2,314 | 2,314 | 2,314 |
| LT Loans \& Advances | 11,554 | 29,457 | 20,849 | 21,014 | 16,960 | 18,349 | 19,852 | 21,481 |
| Total Non-current Assets | 195,712 | 216,590 | 230,120 | 264,587 | 274,422 | 276,878 | 282,688 | 286,695 |
| Inventories | 85,868 | 90,621 | 81,161 | 74,951 | 79,440 | 89,655 | 86,809 | 96,000 |
| Debtors | 19,812 | 19,178 | 24,743 | 26,823 | 40,353 | 25,625 | 24,714 | 27,993 |
| Other assets | 9,743 | 11,109 | 17,471 | 26,523 | 30,852 | 32,394 | 34,014 | 35,715 |
| Cash \& Equivalents | 148,389 | 179,800 | 205,488 | 249,525 | 278,288 | 339,481 | 351,055 | 387,036 |
| Total Current Assets | 263,812 | 300,707 | 328,863 | 377,821 | 428,932 | 487,156 | 496,592 | 546,743 |
| Creditors | 20,205 | 23,393 | 26,593 | 34,962 | 35,096 | 36,298 | 35,495 | 40,203 |
| Other Current Liabilities \& Provns | 99,439 | 42,643 | 44,430 | 57,367 | 65,006 | 60,139 | 66,012 | 72,476 |
| Total Current Liabilities | 119,644 | 66,036 | 71,023 | 92,328 | 100,101 | 96,438 | 101,507 | 112,679 |
| Net Current Assets | 144,168 | 234,672 | 257,839 | 285,493 | 328,831 | 390,718 | 395,086 | 434,064 |
| TOTAL APPLICATION OF FUNDS | 339,880 | 451,261 | 487,960 | 550,080 | 603,253 | 667,596 | 677,773 | 720,759 |

[^4]
## ITC: Results Review 4QFY20

Consolidated Cash Flow

| Particulars (Rs mn) | FY15 | FY16 | FY17 | FY18 | FY19 | FY20P | FY21E | FY22E |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Reported PBT | 143,621 | 154,332 | 160,263 | 174,091 | 191,498 | 200,346 | 186,167 | 212,780 |
| Non-operating \& EO Items | $(5,784)$ | $(5,980)$ | $(2,257)$ | $(3,379)$ | $(17,295)$ | $(23,177)$ | - | - |
| Interest Expenses | $(5,510)$ | $(8,227)$ | $(8,789)$ | $(8,748)$ | 454 | 547 | $(14,949)$ | $(16,169)$ |
| Depreciation | 10,280 | 11,528 | 11,528 | 12,363 | 13,966 | 16,449 | 17,739 | 19,119 |
| Working Capital Change | 312 | $(1,666)$ | 444 | 17,364 | $(4,755)$ | 2,962 | 5,702 | $(4,626)$ |
| Tax Paid | $(44,486)$ | $(50,812)$ | $(54,916)$ | $(59,996)$ | $(58,035)$ | $(50,229)$ | $(51,225)$ | $(58,273)$ |
| OPERATING CASH FLOW ( a ) | 98,432 | 99,176 | 106,273 | 131,694 | 125,834 | 146,898 | 143,434 | 152,830 |
| Capex | $(32,913)$ | $(23,835)$ | $(30,715)$ | $(27,985)$ | $(31,443)$ | $(24,142)$ | $(22,045)$ | $(21,497)$ |
| Free Cash Flow (FCF) | 65,519 | 75,340 | 75,558 | 103,709 | 94,391 | 122,756 | 121,389 | 131,333 |
| Investments | 9,165 | $(34,379)$ | $(10,749)$ | $(50,814)$ | 14,219 | $(54,421)$ | $(15,000)$ | $(15,000)$ |
| Non-operating Income | $(29,006)$ | 18,558 | 8,955 | 7,660 | 2,971 | 8,659 | 15,097 | 16,305 |
| INVESTING CASH FLOW ( b ) | $(52,754)$ | $(39,657)$ | $(32,509)$ | $(71,139)$ | $(14,253)$ | $(69,904)$ | $(21,948)$ | $(20,193)$ |
| Debt Issuance/(Repaid) | 315 | (127) | (132) | 24 | (106) | - | 1 | 2 |
| Interest Expenses | (161) | (324) | (255) | (486) | (980) | (438) | (148) | (136) |
| FCFE | 65,672 | 74,890 | 75,171 | 103,247 | 93,305 | 122,318 | 121,242 | 131,199 |
| Share Capital Issuance | 9,788 | 5,317 | 10,670 | 9,128 | 9,691 | 6,253 | 0 | (0) |
| Dividend | $(48,756)$ | $(61,258)$ | $(83,330)$ | $(70,884)$ | $(77,328)$ | $(87,090)$ | $(124,766)$ | $(111,523)$ |
| Others | $(7,796)$ | $(1,300)$ | 37 | 8 | 37 | (539) | - | - |
| FINANCING CASH FLOW ( c ) | $(46,610)$ | $(57,692)$ | $(73,010)$ | $(62,211)$ | $(68,686)$ | $(81,814)$ | $(124,912)$ | $(111,657)$ |
| NET CASH FLOW (a+b+c) | (932) | 1,827 | 754 | $(1,656)$ | 42,895 | $(4,820)$ | $(3,426)$ | 20,981 |

Key Ratios

|  | FY15 | FY16 | FY17 | FY18 | FY19 | FY20P | FY21E | FY22E |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| PROFITABILITY (\%) |  |  |  |  |  |  |  |  |
| GPM | 61.6 | 65.4 | 62.5 | 63.5 | 64.0 | 64.9 | 64.2 | 64.3 |
| EBITDA Margin | 36.0 | 36.9 | 36.1 | 37.9 | 38.1 | 39.0 | 38.0 | 38.3 |
| EBIT Margin | 33.3 | 34.1 | 33.4 | 35.1 | 35.2 | 35.7 | 34.2 | 34.8 |
| APAT Margin | 25.1 | 24.2 | 24.5 | 25.8 | 26.4 | 30.8 | 29.3 | 29.5 |
| RoE | 32.8 | 25.5 | 23.5 | 22.7 | 23.2 | 24.9 | 21.4 | 23.3 |
| RoIC (or Core RoCE) | 50.8 | 40.3 | 36.4 | 37.2 | 39.2 | 44.8 | 39.3 | 44.2 |
| RoCE | 32.5 | 25.4 | 23.4 | 22.6 | 23.1 | 24.8 | 21.3 | 23.2 |
| EFFICIENCY |  |  |  |  |  |  |  |  |
| Tax Rate (\%) | 32.0 | 36.1 | 34.6 | 34.0 | 33.0 | 22.2 | 25.2 | 25.2 |
| Fixed Asset Turnover (x) | 0.6 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.7 |
| Inventory (days) | 81.5 | 84.4 | 69.2 | 63.0 | 60.0 | 66.2 | 66.5 | 64.9 |
| Debtors (days) | 18.8 | 17.9 | 21.1 | 22.5 | 30.5 | 18.9 | 18.9 | 18.9 |
| Other Current Assets (days) | 9.3 | 10.3 | 14.9 | 22.3 | 23.3 | 23.9 | 26.1 | 24.2 |
| Payables (days) | 19.2 | 21.8 | 22.7 | 29.4 | 26.5 | 26.8 | 27.2 | 27.2 |
| Other Current Liab \& Provns (days) | 94.4 | 39.7 | 37.9 | 48.2 | 49.1 | 44.4 | 50.6 | 49.0 |
| Cash Conversion Cycle (days) | (4.0) | 51.1 | 44.6 | 30.2 | 38.2 | 37.9 | 33.7 | 31.8 |
| Net D/E (x) | (0.5) | (0.4) | (0.4) | (0.5) | (0.5) | (0.5) | (0.5) | (0.5) |
| Interest Coverage (x) | 140.7 | 249.5 | 587.8 | 169.6 | 374.5 | 322.2 | 1,103.3 | 1,382.8 |
| PER SHARE DATA (Rs) |  |  |  |  |  |  |  |  |
| EPS | 8.0 | 7.9 | 8.6 | 9.2 | 10.4 | 12.4 | 11.3 | 13.0 |
| CEPS | 8.9 | 8.8 | 9.6 | 10.2 | 11.6 | 13.7 | 12.8 | 14.5 |
| Dividend | 4.2 | 5.7 | 4.7 | 5.2 | 5.8 | 10.2 | 9.1 | 10.4 |
| Book Value | 26.4 | 35.4 | 38.2 | 43.0 | 47.1 | 52.5 | 53.7 | 57.5 |
| VALUATION |  |  |  |  |  |  |  |  |
| P/E (x) | 24.3 | 24.8 | 22.6 | 21.2 | 18.7 | 15.7 | 17.2 | 15.0 |
| P/BV (x) | 7.4 | 5.5 | 5.1 | 4.5 | 4.1 | 3.7 | 3.6 | 3.4 |
| EV/EBITDA (x) | 15.9 | 15.0 | 14.0 | 12.9 | 11.5 | 10.7 | 11.3 | 9.7 |
| EV/Revenues (x) | 5.7 | 5.5 | 5.1 | 4.9 | 4.4 | 4.2 | 4.3 | 3.7 |
| OCF/EV (\%) | 4.5 | 4.6 | 4.9 | 6.2 | 6.0 | 7.1 | 7.0 | 7.6 |
| FCF/EV (\%) | 3.0 | 3.5 | 3.5 | 4.8 | 4.5 | 6.0 | 5.9 | 6.5 |
| FCFE/Mkt Cap (\%) | 2.8 | 3.2 | 3.2 | 4.3 | 3.9 | 5.1 | 5.1 | 5.5 |
| Dividend Yield (\%) | 2.1 | 2.9 | 2.4 | 2.6 | 2.9 | 5.2 | 4.7 | 5.3 |

[^5]RECOMMENDATION HISTORY


| Date | CMP | Reco | Target |
| :---: | :---: | :---: | :---: |
| 9-Jul-19 | 273 | BUY | 397 |
| 5-Aug-19 | 265 | BUY | 362 |
| 22-Sep-19 | 238 | BUY | 365 |
| 11-Oct-19 | 238 | BUY | 370 |
| 25-Oct-19 | 249 | BUY | 368 |
| 9-Jan-20 | 236 | BUY | 366 |
| 1-Feb-20 | 235 | BUY | 360 |
| 2-Mar-20 | 198 | BUY | 265 |
| 13-Apr-20 | 185 | BUY | 221 |
| 14-Apr-20 | 182 | BUY | 221 |
| 28-Jun-20 | 196 | BUY | 221 |

From $2^{\text {nd }}$ March 2020, we have moved to new rating system

## Rating Criteria

BUY: $\quad>+15 \%$ return potential
ADD: $\quad+5 \%$ to $+15 \%$ return potential
REDUCE: $-10 \%$ to $+5 \%$ return potential
SELL: $\quad>10 \%$ Downside return potential

## Disclosure:

We, Varun Lohchab, PGDM, Naveen Trivedi, MBA \& Aditya Sane, CA, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.
Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of $1 \%$ or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does not have any material conflict of interest.
Any holding in stock -NO
HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

## Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.
This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.
If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.
Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.
This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.
HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.
HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.
HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.
HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.
HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.
HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.
Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.
HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400042 Phone: (022) 30753400 Fax: (022) 24965066 Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 30453600 HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN U67120MH2000PLC152193

## HDFC securities

Institutional Equities
Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park,
Senapati Bapat Marg, Lower Parel, Mumbai - 400013
Board: +91-22-6171-7330 www.hdfcsec.com


[^0]:    Source: Company, HSIE Research

[^1]:    Source: Company, HSIE Research

[^2]:    Source: Company, HSIE Research

[^3]:    Source: Company, HSIE Research

[^4]:    Source: Company, HSIE Research

[^5]:    Source: Company, HSIE Research

